1.
Neuropsychopharmacol Hung
; 15(2): 105-17, 2013 Jun.
Article
in Hungarian
| MEDLINE
| ID: mdl-23817361
ABSTRACT
When treating schizophrenia and other psychotic disorders, clinicians often encounter the problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life. The uncertain oral drug taking habits may lead to relapses and rehospitalizations. Using second generation long acting injectables we have more possibilities to avoid these problems. This review attempts to present and describe the pharmacological background of the modern long acting injectables including patient cases where olanzapine pamoate long acting injectable provided remission and better quality of life for the patients.